Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer

Cancer Research

Volumn 73, Issue 4, 2013, Pages 1276-1286

  McCormack, Emmet ^a   Silden, Elisabeth ^a   West, Richard M ^b   Pavlin, Tina ^a   Micklem, David R ^a,b   Lorens, James B ^a,b   Haug, Bengt Erik ^a   Cooper, Michael E ^d   Gjertsen, Bjorn Tore ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b Department of Biomedicine ^*  (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d GE HEALTHCARE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCY5S; FLUORESCENT DYE; METRONIDAZOLE; NITROREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; FLUORESCENCE IMAGING; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA; LUNG CANCER; METASTASIS; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TIME DOMAIN OPTICAL IMAGING;

ANIMALS; ANTI-INFECTIVE AGENTS; CARBOCYANINES; CELL LINE, TUMOR; CELL SURVIVAL; ESCHERICHIA COLI PROTEINS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; LUCIFERASES; MAGNETIC RESONANCE IMAGING; METRONIDAZOLE; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; NEOPLASMS; NITROIMIDAZOLES; NITROREDUCTASES; REPRODUCIBILITY OF RESULTS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874308099     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2649     Document Type: Article

References (38)

1. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9.
2. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008;7:591-607. (Pubitemid 351927724)
3. McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A, et al. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization. Mol Imaging 2007;6:193-204. (Pubitemid 47152706)
4. Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials 2011;32:7127-38.
5. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170:793-804. (Pubitemid 47339349)
6. KumarAT, Chung E, Raymond SB, van de Water JA, Shah K, Fukumura D, et al. Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast. Opt Lett 2009;34:2066-8.
7. Campbell RE, Tour O, Palmer AE, et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A 2002;99:7877-82. (Pubitemid 34650973)
8. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004;22:1567-72. (Pubitemid 40039460)
9. Wang L, Jackson WC, Steinbach PA, Tsien RY. Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc Natl Acad Sci U S A 2004;101:16745-9.
10. Merzlyak EM, Goedhart J, Shcherbo D, Bulina ME, Shcheglov AS, Fradkov AF, et al. Bright monomeric red fluorescent protein with an extended fluorescence lifetime. Nat Methods 2007;4:555-7.
11. Filonov GS, Piatkevich KD, Ting LM, Zhang J, Kim K, Verkhusha VV. Bright and stable near-infrared fluorescent protein for in vivo imaging. Nat Biotechnol 2011;29:751-61.
12. Prescher JA, Contag CH. Guided by the light: visualizing biomolecular processes in living animals with bioluminescence. Curr OpinChemBiol 2010;14:80-9.
13. Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, et al. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol 2004;31:811-6.
14. Cui L, Zhong Y, Zhu W, Xu Y, Du Q,Wang X, et al. A new prodrugderived ratiometric fluorescent probe for hypoxia: high selectivity of nitroreductase and imaging in tumor cell. Org Lett 2011;13: 928-31.
15. Thorne SH, Barak Y, Liang W, Bachmann MH, Rao J, Contag CH, et al. CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy. Mol Cancer Ther 2009;8:333-41.
16. Cellier M, Fabrega OJ, Fazackerley E, James AL, Orenga S, Perry JD, et al. 2-Arylbenzothiazole, benzoxazole and benzimidazole derivatives as fluorogenic substrates for the detection of nitroreductase and aminopeptidase activity in clinically important bacteria. Bioorg Med Chem 2011;19:2903-10.
17. James AL, Perry JD, Jay C, Monget D, Rasburn JW, Gould FK. Fluorogenic substrates for the detection of microbial nitroreductases. Lett Appl Microbiol 2001;33:403-8.
18. Bhaumik S, Sekar TV, Depuy J, Klimash J, Paulmurugan R. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals. Gene Ther 2012;19:295-302.
19. de la Zerda A, Bodapati S, Teed R, Schipper ML, Keren S, Smith BR, et al. A comparison between time domain and spectral imaging systems for imaging quantum dots in small living animals. Mol Imaging Biol 2010;12:500-8.
20. Keren S, Gheysens O, Levin CS, Gambhir SS. A comparison between a time domain and continuous wave small animal optical imaging system. IEEE Trans Med Imaging 2008;27:58-63.
21. Lorens JB, Bennett MK, Pearsall DM, Throndset WR, Rossi AB, Armstrong RJ, et al. Retroviral delivery of peptide modulators of cellular functions. Mol Ther 2000;1:438-47.
22. Lorens JB, Pearsall DM, Swift SE, Peelle B, Armstrong R, Demo SD, et al. Stable, stoichiometric delivery of diverse protein functions. J Biochem Biophys Methods 2004;58:101-10. (Pubitemid 38230805)
23. Lorens JB, Jang Y, Rossi AB, PayanDG, BogenbergerJM. Optimization of regulated LTR-mediated expression. Virology 2000;272:7-15. (Pubitemid 30429425)
24. Gjertsen BT, Cressey LI, Ruchaud S, Houge G, Lanotte M, Doskeland SO. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. J Cell Sci 1994;107 (Pt 12):3363-77.
25. McCormack E, Haaland I, Venas G, Forthun RB, Huseby S, Gausdal G, et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 2012; 26:910-7.
26. West RM, Ismail Rinventors; GE Healthcare UK Limited, Amersham (GB), assignee. Method and reagent for measuring nitroreductase enzyme activity. United States patent. US 7,579,140 B2. 2009.
27. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010;107:1124-9.
28. Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 2011;17:3638-48.
29. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther 1997;8: 709-17. (Pubitemid 27202057)
30. Willems B, Buttner A, Huysseune A, Renn J, Witten PE, Winkler C. Conditional ablation of osteoblasts in medaka. Dev Biol 2012;364: 128-37.
31. Shcherbo D, Shemiakina II, Ryabova AV, et al. Near-infrared fluorescent proteins. Nat Methods 2010;7:827-9.
32. Hoffman RM. Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clin Exp Metastasis 2009; 26:345-55.
33. Deliolanis NC, Wurdinger T, Pike L, Tannous BA, Breakefield XO, Weissleder R, et al. In vivo tomographic imaging of red-shifted fluorescent proteins. Biomed Opt Express 2011;2:887-900.
34. Hojman P, Eriksen J, Gehl J. In vivo imaging of far-red fluorescent proteins after DNA electrotransfer to muscle tissue. Biol Proced Online 2009;11:253-62.
35. Zhao H, Doyle TC, Coquoz O, Kalish F, Rice BW, Contag CH. Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J Biomed Opt 2005;10:41210.
36. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther 2009;17:1292-9.
37. Palmer DH, Mautner V, Mirza D, Oliff S, GerritsenW, van der Sijp JR, et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004;22: 1546-52. (Pubitemid 41079791)
38. Onion D, Patel P, Pineda RG, James N, Mautner V. Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. Hum Gene Ther 2009;20:1249-58.